Top

Published in:

01-12-2017 | Original Article

Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers—a Study from Indian Regional Cancer Centre

Authors: C. S. Smitha, Babu M. C. Suresh, J. A. Linu, K. C. Lakshmaiah, Babu K. Govind, D. Lokanatha, R. K. Pretesh

Published in: Indian Journal of Surgical Oncology | Issue 4/2017

Abstract

Mutation analysis of the KRAS oncogene is established as a predictive biomarker in Colorectal cancer (CRC). Many prospective clinical trials have shown that only CRCs with wild-type KRAS respond to anti-epidermal growth factor receptor (EGFR) treatment. Hence, mutation analysis is mandatory before treatment of metastatic CRCs. There are very few studies on the KRAS mutation status in the Indian setting. Hence, this study was done to document the patterns of KRAS mutations in CRCs reporting to a regional cancer centre in South India. Among 150 cases of metastatic colorectal cancer reporting over a period of 20 months, 48 random cases were analyzed for the KRAS mutational status of codons 12 and 13 of the KRAS gene by genomic sequencing. KRAS mutations in codons 12 and 13 were present in 9/48 (18.75%) of all analyzed CRCs. The common types of mutations were glycine to aspartate on codon 12 (p.G12D), glycine to valine on codon 12 (p.G12 V), and glycine to aspartate on codon 13 (p.G13D).

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMed

Karapetis CS, Khambata Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMed

Barbacid M (1987) Ras genes. Annu Rev Biochem 56:779–827CrossRefPubMed

Macara IG, Lounsbury KM, Richards SA, McKiernan C, Bar-Sagi D (1997) The Ras superfamily of GTPases. FASEB J 10:625–630

Cardenas-Ramos SG, Alcazar-Gonzalez G, Reyes-Cortes LM, Torres-Grimaldo AA, Calderon-Garciduenas AL, Morales-Casas J (2014) The frequency and type of KRAS mutations in Mexican patients with colorectal cancer. Am J Clin Oncol 40(3):274–276CrossRef

Rodenhuis S, Wetering M, Mooi W, Evers S, Zandwijk N, Bos J (1987) Mutational activation of the K-Ras oncogene. N Engl J Med 317:929–935CrossRefPubMed

Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA (2009) Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer 46:219–225CrossRefPubMed

Elsamany SA, Alzahrani AS, Mohamed MM, Elmorsy SA, Zekri JE, Al-Shehri AS et al (2014) Clinico pathological patterns and survival outcome of colorectal cancer in young patients: western Saudi Arabia experience. Asian Pac J Cancer Prev 15:5239–5243CrossRefPubMed

Zocche DM, Ramirez C, Fontao FM, Costa LD, Redal MA (2015) Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. Front Genet 6:116CrossRefPubMedPubMedCentral

10.

Schubber S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308CrossRef

11.

De Roock W, Jonker DJ, DiNicolantonio F, Sartore-Bianchi A, Tu D, Siena S et al (2010) Association of KRAS p.G13D mutation without come in patients with chemotherapy refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820CrossRefPubMed

12.

Dattatreya S (2013) Metastatic colorectal cancer prolonging overall survival with targeted therapies. South Asian J Cancer 2:179–185CrossRefPubMedPubMedCentral

13.

Douillard JY, Olineret KS, Siena S, Tabernero J, Burkes R, Barugel M et al (2013) Panitimumab FOLFOX4 treatment and Ras mutations in colorectal cancer. N Engl J Med 369:1023–1034CrossRefPubMed

14.

National Comprehensive Cancer Network (2015) Colon cancer Version 2. Available from: http://www.nccn.org/professionals/physician_gls/pdf/colon. pdf. [Last accessed on 2015 Nov 30]

15.

Patil H, Korde R, Kapat A (2013) KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. Med Oncol 30:617CrossRefPubMed

16.

Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage and survival: a population-based study. Cancer Epidemiol Biomark Prev 9:1193–1197

17.

Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J et al (2011) Value of mismatch repair KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261–1270CrossRefPubMed

18.

Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations without come in patients with metastatic colorectal cancer treated with first line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577CrossRefPubMed

Title: Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers—a Study from Indian Regional Cancer Centre
Authors: C. S. Smitha
Babu M. C. Suresh
J. A. Linu
K. C. Lakshmaiah
Babu K. Govind
D. Lokanatha
R. K. Pretesh
Publication date: 01-12-2017
Publisher: Springer India
Published in: Indian Journal of Surgical Oncology / Issue 4/2017
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI: https://doi.org/10.1007/s13193-017-0704-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers—a Study from Indian Regional Cancer Centre

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

An Overview of the Current Management of Bilobar Colorectal Liver Metastases

Ovarian Metastases of Colorectal Origin: Treatment Patterns and Factors Affecting Outcomes

Postoperative Delirium in Indian Patients Following Major Abdominal Surgery for Cancer: Risk Factors and Associations

CRS and HIPEC for PMP—Use of the LC-CUSUM to Determine the Number of Procedures Required to Attain a Minimal Level of Proficiency in Delivering the Combined Modality Treatment

Quality of Life After “Total Mesorectal Excision (TME)” for Rectal Carcinoma: a Study from a Tertiary Care Hospital in Northern India

A Prospective Study of Distal Microscopic Spread in Rectal Cancer After Neoadjuvant Chemoradiation in Pinned and Unpinned Specimen